X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Lagevrio (molnupiravir) is an investigational, orally administered nucleoside analog that accumulates errors in the viral genome leading in inhibition of SARS-CoV-2 replication, the causative agent of COVID-19.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Lagevrio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
Details:
A preliminary analysis in highly-vaccinated adults mostly <65 years of age, showed no evidence of difference between LAGEVRIO (molnupiravir) added to usual care compared to usual care alone for reduction of hospitalizations and deaths through Day 28.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Lagevrio
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
Under the terms of the contemplated collaboration, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga (Ansuvimab-zykl) in the United States and Canada, and Ridgeback Bio will serve as the global access partner for Ebanga™.
Lead Product(s): Ansuvimab-zykl
Therapeutic Area: Infections and Infectious Diseases Product Name: Ebanga
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Emergent BioSolutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 07, 2022
Details:
Analyses of pre-specied exploratory endpoints indicate that a lower proportion of LAGEVRIO (Molnupiravir)-treated participants in MTT population had an acute care visit or a COVID-19-related acute care visit versus placebo-treated participants in the MITT population.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Lagevrio
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
Lagevrio (molnupiravir), an investigational oral antiviral medicine, cleared infectious SARS-CoV-2 faster than placebo among patients who had infectious virus at baseline, resulting in no infectious virus detected at Day 3, 5 or 10.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Lagevrio
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2022
Details:
The studies used established cell-based assays to evaluate the antiviral activity of molnupiravir and other COVID-19 antiviral agents against SARS-CoV-2 variants of concern, including Omicron.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-4482
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2022
Details:
The approval is based on positive results from a planned interim analysis from Phase 3 MOVe-OUT clinical trial by Japan’s Ministry of Health, Labor and Welfare, in Japan LAGEVRIO® (molnupiravir) is planned trademark for molnupiravir.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-4482
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 24, 2021
Details:
Merck’s submission to the FDA for EUA is based on the positive results of Molnupiravir an investigational oral antiviral medicine, for the treatment of mild to moderate COVID-19 in adults.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-4482
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2021
Details:
Molnupiravir investigational, orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2, the causative agent of COVID-19.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-4482
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 26, 2021
Details:
MK-4482 or EIDD-2801 (Molnupiravir) is an investigational, orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2, the causative agent of COVID-19.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-4482
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
